Abstract
Persistent low-level viremia during chronic hepatitis B therapy can promote drug-resistant mutations, liver fibrosis progression and even hepatocellular carcinoma occurrence, which further seriously affect the prognosis of patients. Herein, we hope to clarify and analyze the possible occurrence mechanisms and clinical outcomes of low-level viremia by sorting out the key points, so as to assist in the adjustment of individualized treatment plans and provide references for the diagnosis and treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
